Intellipharmaceutics files new drug application for generic Protonix

TORONTO Intellipharmaceutics has filed an abbreviated new drug application for a generic drug designed to treat gastrointestinal issues, the drug maker said.

Intellipharmaceutics said its pantoprazole sodium delayed-release tablets -- a generic version of Protonix -- inhibits gastric acid secretion and is prescribed for the short-term treatment of such conditions as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome.

Sales of pantoprazole sodium delayed-release tablets in the United States were approximately $1.8 billion in 2009.

"I am extremely pleased with the progress we continue to make with the advancement of our product pipeline," said Isa Odidi, Intellipharmaceutics CEO. "Protonix is the second ANDA we have filed with the FDA this year and, together with Focalin XR and Effexor XR, it represents another potential source of future revenue from our company's ANDA pipeline."

Login or Register to post a comment.